Reduced efficacy of topical corticosteroid in preventing cytarabine-induced kerato-conjunctivitis in patients receiving high-dose cytarabine and total body irradiation for allogeneic hematopoietic stem cell transplantation

Takehiko Mori, M. Watanabe, T. Kurotori-Sotome, C. Ito, K. Yamada, T. Yashima, N. Kobayashi, S. Kondo, Y. Aisa, Jun Kato, Y. Ogawa, Kazuo Tsubota, Naoyuki Shigematsu, A. Kubo, Y. Ikeda, Shinichiro Okamoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This study aimed to retrospectively evaluate the incidence of kerato-conjunctivitis in patients receiving TBI followed by high-dose cytarabine, and to clarify how effectively topical corticosteroid eye drops prevent kerato-conjunctivitis in these patients. Fifty-three patients who received cytarabine at a dose of 3 g/m2 every 12h for 4 days after receiving TBI (12 Gy) as a conditioning for allogeneic hematopoietic stem cell transplantation (HSCT) were evaluated. For the prophylaxis of kerato-conjunctivitis, all patients received betamethasone sodium phosphate eye drops every 6h, starting 1 day before the first dose of cytarabine and continuing until 1 day after the last dose of cytarabine or the complete resolution of ocular symptoms. For grading of kerato-conjuncitivitis, the National Cancer Institute-Common Toxicity Criteria were used. Among the 53 patients, the grades of kerato-conjunctivitis were grade 0 in 13 patients, grade 1 in 6 patients (11.3%), grade 2 in 10 patients (18.9%) and grade 3 in 25 patients (47.2%). These results strongly suggest that topical corticosteroid eye drops could not effectively prevent the development of cytarabine-induced kerato-conjunctivitis in HSCT recipients who receive high-dose cytarabine following TBI. Further investigation into a more effective prophylaxis for cytarabine-induced kerato-conjunctivitis in this setting is required.

Original languageEnglish
Pages (from-to)197-199
Number of pages3
JournalBone Marrow Transplantation
Volume42
Issue number3
DOIs
Publication statusPublished - 2008

Fingerprint

Conjunctivitis
Whole-Body Irradiation
Hematopoietic Stem Cell Transplantation
Cytarabine
Adrenal Cortex Hormones
Ophthalmic Solutions
National Cancer Institute (U.S.)
Incidence

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Reduced efficacy of topical corticosteroid in preventing cytarabine-induced kerato-conjunctivitis in patients receiving high-dose cytarabine and total body irradiation for allogeneic hematopoietic stem cell transplantation. / Mori, Takehiko; Watanabe, M.; Kurotori-Sotome, T.; Ito, C.; Yamada, K.; Yashima, T.; Kobayashi, N.; Kondo, S.; Aisa, Y.; Kato, Jun; Ogawa, Y.; Tsubota, Kazuo; Shigematsu, Naoyuki; Kubo, A.; Ikeda, Y.; Okamoto, Shinichiro.

In: Bone Marrow Transplantation, Vol. 42, No. 3, 2008, p. 197-199.

Research output: Contribution to journalArticle

@article{191607564d104879b5102f93e396dcf4,
title = "Reduced efficacy of topical corticosteroid in preventing cytarabine-induced kerato-conjunctivitis in patients receiving high-dose cytarabine and total body irradiation for allogeneic hematopoietic stem cell transplantation",
abstract = "This study aimed to retrospectively evaluate the incidence of kerato-conjunctivitis in patients receiving TBI followed by high-dose cytarabine, and to clarify how effectively topical corticosteroid eye drops prevent kerato-conjunctivitis in these patients. Fifty-three patients who received cytarabine at a dose of 3 g/m2 every 12h for 4 days after receiving TBI (12 Gy) as a conditioning for allogeneic hematopoietic stem cell transplantation (HSCT) were evaluated. For the prophylaxis of kerato-conjunctivitis, all patients received betamethasone sodium phosphate eye drops every 6h, starting 1 day before the first dose of cytarabine and continuing until 1 day after the last dose of cytarabine or the complete resolution of ocular symptoms. For grading of kerato-conjuncitivitis, the National Cancer Institute-Common Toxicity Criteria were used. Among the 53 patients, the grades of kerato-conjunctivitis were grade 0 in 13 patients, grade 1 in 6 patients (11.3{\%}), grade 2 in 10 patients (18.9{\%}) and grade 3 in 25 patients (47.2{\%}). These results strongly suggest that topical corticosteroid eye drops could not effectively prevent the development of cytarabine-induced kerato-conjunctivitis in HSCT recipients who receive high-dose cytarabine following TBI. Further investigation into a more effective prophylaxis for cytarabine-induced kerato-conjunctivitis in this setting is required.",
author = "Takehiko Mori and M. Watanabe and T. Kurotori-Sotome and C. Ito and K. Yamada and T. Yashima and N. Kobayashi and S. Kondo and Y. Aisa and Jun Kato and Y. Ogawa and Kazuo Tsubota and Naoyuki Shigematsu and A. Kubo and Y. Ikeda and Shinichiro Okamoto",
year = "2008",
doi = "10.1038/bmt.2008.152",
language = "English",
volume = "42",
pages = "197--199",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Reduced efficacy of topical corticosteroid in preventing cytarabine-induced kerato-conjunctivitis in patients receiving high-dose cytarabine and total body irradiation for allogeneic hematopoietic stem cell transplantation

AU - Mori, Takehiko

AU - Watanabe, M.

AU - Kurotori-Sotome, T.

AU - Ito, C.

AU - Yamada, K.

AU - Yashima, T.

AU - Kobayashi, N.

AU - Kondo, S.

AU - Aisa, Y.

AU - Kato, Jun

AU - Ogawa, Y.

AU - Tsubota, Kazuo

AU - Shigematsu, Naoyuki

AU - Kubo, A.

AU - Ikeda, Y.

AU - Okamoto, Shinichiro

PY - 2008

Y1 - 2008

N2 - This study aimed to retrospectively evaluate the incidence of kerato-conjunctivitis in patients receiving TBI followed by high-dose cytarabine, and to clarify how effectively topical corticosteroid eye drops prevent kerato-conjunctivitis in these patients. Fifty-three patients who received cytarabine at a dose of 3 g/m2 every 12h for 4 days after receiving TBI (12 Gy) as a conditioning for allogeneic hematopoietic stem cell transplantation (HSCT) were evaluated. For the prophylaxis of kerato-conjunctivitis, all patients received betamethasone sodium phosphate eye drops every 6h, starting 1 day before the first dose of cytarabine and continuing until 1 day after the last dose of cytarabine or the complete resolution of ocular symptoms. For grading of kerato-conjuncitivitis, the National Cancer Institute-Common Toxicity Criteria were used. Among the 53 patients, the grades of kerato-conjunctivitis were grade 0 in 13 patients, grade 1 in 6 patients (11.3%), grade 2 in 10 patients (18.9%) and grade 3 in 25 patients (47.2%). These results strongly suggest that topical corticosteroid eye drops could not effectively prevent the development of cytarabine-induced kerato-conjunctivitis in HSCT recipients who receive high-dose cytarabine following TBI. Further investigation into a more effective prophylaxis for cytarabine-induced kerato-conjunctivitis in this setting is required.

AB - This study aimed to retrospectively evaluate the incidence of kerato-conjunctivitis in patients receiving TBI followed by high-dose cytarabine, and to clarify how effectively topical corticosteroid eye drops prevent kerato-conjunctivitis in these patients. Fifty-three patients who received cytarabine at a dose of 3 g/m2 every 12h for 4 days after receiving TBI (12 Gy) as a conditioning for allogeneic hematopoietic stem cell transplantation (HSCT) were evaluated. For the prophylaxis of kerato-conjunctivitis, all patients received betamethasone sodium phosphate eye drops every 6h, starting 1 day before the first dose of cytarabine and continuing until 1 day after the last dose of cytarabine or the complete resolution of ocular symptoms. For grading of kerato-conjuncitivitis, the National Cancer Institute-Common Toxicity Criteria were used. Among the 53 patients, the grades of kerato-conjunctivitis were grade 0 in 13 patients, grade 1 in 6 patients (11.3%), grade 2 in 10 patients (18.9%) and grade 3 in 25 patients (47.2%). These results strongly suggest that topical corticosteroid eye drops could not effectively prevent the development of cytarabine-induced kerato-conjunctivitis in HSCT recipients who receive high-dose cytarabine following TBI. Further investigation into a more effective prophylaxis for cytarabine-induced kerato-conjunctivitis in this setting is required.

UR - http://www.scopus.com/inward/record.url?scp=50049105747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50049105747&partnerID=8YFLogxK

U2 - 10.1038/bmt.2008.152

DO - 10.1038/bmt.2008.152

M3 - Article

VL - 42

SP - 197

EP - 199

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -